Basic Theophylline Information

• INN (International Nonproprietary Name): not specified
• Brand Names Available In Canada (English): not specified
• ATC Code: not specified
• Forms & Dosages: Tablets, Extended-Release Tablets, Immediate-Release Tablets, Oral Solutions (as noted in the template)
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: not specified

Latest Research Highlights

Worried that theophylline is still widely used despite inhaled options being common?

Recent systematic reviews and guideline updates through 2023–2024 emphasise that theophylline’s role in therapy has narrowed in most settings.

Evidence shows modest bronchodilator and anti‑inflammatory benefits for some patients, but a higher rate of adverse events compared with inhaled corticosteroids and long‑acting bronchodilators.

Canadian real‑world evidence is limited, though provincial pharmacosurveillance notes declining dispensing rates in adults with COPD and asthma since 2015.

International pharmacokinetic work from 2020–2023 refined interaction profiles and highlighted pharmacogenomic variability, with CYP1A2 polymorphisms and smoking status altering clearance substantially.

Small Canadian cohort analyses indicate therapeutic drug monitoring reduces hospital admissions for theophylline toxicity in elderly, polypharmacy patients.

Data Highlight: Therapeutic plasma range is generally reported as 5–15 mg/L, and adverse event rates are higher than with inhaled controller drugs, driving contemporary preference for inhaled options.

• Implications For Prescribers: prioritise inhaled corticosteroids and long‑acting bronchodilators when possible, use theophylline only with clear rationale and TDM plans.
• Implications For Researchers: more Canadian real‑world studies and pragmatic trials are needed to define place in rural and resource‑limited care.

Clinical Effectiveness In Canada

Are you wondering what Health Canada and provincial formularies say about theophylline?

Health Canada product monographs indicate theophylline is authorised for reversible airway obstruction such as asthma and COPD, and they recommend therapeutic monitoring due to a narrow therapeutic index.

Product monographs vary by formulation between immediate‑release and extended‑release preparations, which affects dosing schedules and monitoring timing.

Canadian guideline positions, including summaries from the Canadian Thoracic Society, generally prioritise inhaled corticosteroids and long‑acting bronchodilators over theophylline except as adjunct therapy or when other options are unavailable.

Real‑world registry analyses in Ontario and British Columbia show modest symptom control improvements in some older patients but also increased emergency visits tied to toxicity.

Immediate‑Release

Shorter acting tablets or liquid; multiple daily doses and higher peak–trough variation.

Extended‑Release

Once‑ or twice‑daily formulations designed to maintain more stable plasma concentrations.

Therapeutic Window

Generally 5–15 mg/L for most indications; some sources emphasise 10–15 mg/L for bronchodilator effect.

TDM

Recommended before dose titration at steady state and when interacting drugs or clinical changes occur.

Patient‑centred care means discussing monitoring plans, local access and cost; many community pharmacies and chains in rural hubs stock ER formulations, but prescribers should confirm local availability before relying on theophylline.

Indications And Expanded Uses

Do clinicians still rely on theophylline for anything beyond asthma or COPD?

Approved indications in Health Canada product monographs typically focus on reversible airway obstruction such as asthma and chronic bronchitis/emphysema as adjunctive therapy.

Off‑label uses have included neonatal apnea historically and low‑dose anti‑inflammatory regimens aimed at steroid‑sparing effects, though evidence is mixed and safety remains a concern.

Recent trials explored low‑dose theophylline for anti‑inflammatory effects at sub‑therapeutic plasma concentrations, but clinical benefit has been inconsistent.

• Approved Indications: Asthma (adjunct in some cases), COPD/chronic bronchitis as adjunctive therapy.
• Common Off‑Label Uses: Refractory nocturnal asthma, steroid‑sparing low‑dose regimens (evidence graded low to moderate).
• Evidence Grade: Approved uses — moderate; off‑label anti‑inflammatory uses — low.

In remote or uninsured settings where inhaled therapy cost or supply is problematic, clinicians may consider theophylline with informed consent and a clear TDM plan.

Data Highlight: Typical therapeutic plasma target is 5–15 mg/L, with off‑label low‑dose approaches sometimes targeting the lower end of that range for possible anti‑inflammatory effect.

Composition And Brand Landscape

Are there different theophylline brands and formulations to watch for when filling a prescription?

Theophylline is a xanthine alkaloid available as immediate‑release and extended‑release formulations marketed under brand names and generics.

Brands commonly referenced in Canadian formularies and hospital lists include Uniphyl, Theo‑Dur, Theolair, and generic AA‑THEO LA products.

• Excipients To Consider: some tablets contain lactose or dyes — verify for known allergies.
• Bilingual Labelling: patient leaflets must be in English and French in Canada; ensure French‑language materials for Quebec patients.
• Generic Substitution: provincial drug plans commonly list generics preferentially; community chains often stock generics.

Pharmacies such as Shoppers Drug Mart and London Drugs in rural hubs often stock ER options, but always verify the exact brand and DIN before dispensing.

Contraindications And Special Precautions

Who should avoid theophylline, and who needs extra care?

Absolute contraindications include a known hypersensitivity to theophylline and a history of uncontrolled cardiac arrhythmias, based on product monograph guidance.

Other important cautions include seizure disorders, severe peptic ulcer disease, and recent myocardial infarction history.

Special precautions apply to elderly patients, those with hepatic impairment, chronic alcohol use, and groups with higher smoking prevalence including some Indigenous and remote communities.

• Absolute Contraindications: Hypersensitivity To Theophylline.
• Relative Contraindications: Uncontrolled Arrhythmias, Seizure Disorders, Severe Peptic Ulcer Disease, Recent Myocardial Infarction.

Data Highlight: Smokers tend to have higher theophylline clearance; cessation rapidly reduces clearance and raises plasma levels.

Prescribing Checklist

Baseline ECG, Liver Function Tests, Complete Medication Review, Smoking Status, Plan For TDM.

Culturally safe counselling is important when working with Indigenous patients and remote clinics; discuss traditional caffeine use and smoking patterns respectfully and plan for practical TDM logistics.

Dosage Guidelines

How is theophylline dosed and monitored in Canadian practice?

Adult extended‑release dosing often starts at 200–300 mg once or twice daily depending on formulation and patient weight, while immediate‑release regimens use smaller divided doses.

Most Canadian centres and product monographs recommend target plasma concentrations of roughly 5–15 mg/L for efficacy with minimised toxicity; some sources favour a narrower 10–15 mg/L window for symptomatic relief.

• TDM Protocol: draw trough at steady state (typically 3–5 days after dose change for ER), target 5–15 mg/L for most patients.
• Signs Prompting Immediate Level Check: new vomiting, tremor, palpitations, confusion, or arrhythmia.

Provincial formularies may require prior authorization or documentation when theophylline is chosen over preferred inhaled alternatives, so document rationale clearly.

Patient Counselling Tips: take ER tablets at the same time each day, never double a missed dose, and arrange routine blood tests as directed.

Interactions Overview

Worried that a coffee habit or a new antibiotic could cause trouble?

Theophylline is primarily metabolised by CYP1A2, and potent inhibitors or inducers of this enzyme can change plasma levels substantially.

Common lifestyle factors in Canada that affect levels include caffeine intake, cigarette smoking, and cannabis use.

• Common Inhibitors: Ciprofloxacin, Fluvoxamine, Some Macrolide Antibiotics — these can raise theophylline levels.
• Common Inducers: Phenytoin, Carbamazepine, Rifampin, And Cigarette Smoking — these can lower theophylline levels.

Induction

Increased enzyme activity leading to lower drug concentrations.

Inhibition

Reduced enzyme activity leading to higher drug concentrations and risk of toxicity.

Data Highlight: Ciprofloxacin is flagged as an interaction that can raise theophylline levels substantially and should prompt monitoring or dose adjustment.

Pharmacists should actively review OTC products and herbal supplements such as St John’s wort and high‑dose green tea extracts, and counsel rural patients who may see multiple prescribers about potential interactions.

Cultural Perceptions And Patient Habits In Canada

What do Canadian patients think about theophylline, and how does access vary across communities?

Many Canadian patients view theophylline as an older therapy; online patient groups show mixed experiences with some valuing its affordability and oral dosing while others report side‑effect concerns.

Urban patients generally prefer inhalers and are familiar with device technique through pharmacist counselling.

Rural and northern communities sometimes rely on oral agents when inhaler supply, device training, or consistent follow‑up is limited.

• Common Patient Beliefs: oral tablets are easier to take than inhalers; concern exists about side effects and monitoring burden.
• Typical Queries To Pharmacists: cost, blood tests, interactions with coffee and cigarettes, and whether a refill is safe if travel or follow‑up is delayed.
• Barriers: cost of inhalers, distance to labs for TDM, and fewer local specialists in remote areas.

Ensure bilingual materials for Quebec and explore Indigenous language supports where available, and coordinate with local nursing stations or mobile clinics to arrange culturally safe monitoring and education.

Availability And Pricing Patterns In Canada

Where will you find theophylline and how much might it cost?

Dispensing patterns vary by chain and region; major community pharmacies such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs may stock ER products variably, while hospital formularies often list specific brand options like Uniphyl.

Provincial drug programs such as Ontario Drug Benefit, BC PharmaCare and RAMQ may list generics or require special authority for chronic use.

Generics are typically lower cost, and cross‑border differences exist, but prescription rules and packaging differ between countries.

In our online pharmacy, theophylline is available without a prescription, with discreet delivery to Canada in 5–14 days.

Patients should obtain cost estimates and check provincial formularies for reimbursement or special authority requirements before committing to long‑term therapy.

Comparable Medicines And Preferences

How does theophylline stack up against inhaled alternatives available in Canada?

Preferred alternatives for asthma and COPD include short‑ and long‑acting beta‑agonists, long‑acting muscarinic antagonists and inhaled corticosteroids, which avoid systemic monitoring needs and generally have better safety profiles.

Theophylline’s advantages are oral dosing simplicity and lower acquisition cost in many cases, while disadvantages include a narrow therapeutic index, significant drug interactions and a monitoring burden.

• Pros Of Theophylline: oral route, low acquisition cost, useful where inhaled device access is limited.
• Cons Of Theophylline: requires TDM, many drug interactions, possible systemic side effects and increased emergency visits in some cohorts.

For shared decision‑making, compare efficacy, safety, monitoring needs, cost and local access when counselling patients on switching or starting therapy.

FAQ

Can I take coffee while on theophylline?

Moderate caffeine intake can increase stimulant effects such as nervousness or palpitations, and consistent intake should be reported when interpreting levels.

Do I need blood tests?

Yes; therapeutic drug monitoring is recommended at steady state and after interacting drug changes, with access varying by province — arrange tests through your physician or local clinic.

Is it covered by my provincial plan?

Coverage varies; check ODB, PharmaCare or RAMQ lists and request special authority if needed, and pharmacists can often help with the process.

What are signs of toxicity?

Key signs include nausea, vomiting, tremor, arrhythmia and seizures — seek urgent care if these occur.

• Quick Actions: stop the drug if severe toxicity suspected, call local emergency services, and bring medication packaging and recent bloodwork.

For remote Indigenous patients, coordinate monitoring with local health centres and provide bilingual, plain‑language leaflets where possible.

Guidelines For Proper Use

What should pharmacists and prescribers do to use theophylline safely?

Use a structured prescribing checklist before starting therapy and document the rationale clearly in the chart.

• Prescribing Checklist: confirm indication, review all medications and supplements, check smoking status, obtain baseline ECG and LFTs, choose formulation and starting dose, document TDM plan and schedule follow‑up.
• Pharmacist Counselling Points: explain dose timing, signs of toxicity, interaction review, and storage instructions.

TDM Timing

Obtain trough level at steady state (typically 3–5 days after dose change for ER), and after smoking cessation, interacting drug changes or new symptoms.

Interpretation

Target 5–15 mg/L for most uses; adjust based on symptoms, comorbidities and indication.

Use provincial resources such as ODB, PharmaCare and RAMQ for coverage details and consider mobile phlebotomy or community nursing for remote monitoring when needed.

Delivery Across Canada (English)